[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100553110":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":25,"responsibleParty":43,"collaborators":10,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":10,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":58,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":10,"overallStatus":27,"whyStopped":10,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group",null,"Glofitamab",[13],"Drug: Glofitamab",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":10},"DRUG","Glofitamab given in standard dosage",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Jing Ruan","CONTACT","+8615201435860","15201435860@163.com",[26],{"facility":5,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Beijing","Beijing Municipality","100730","China","CN",{"type":34,"coordinates":35},"Point",[36,37],116.39723,39.9075,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":10,"phoneExt":10,"email":42},"Wei Zhang","zhangwei3840@126.com",{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100553110","glofitamab-in-chinese-patients-with-rr-dlbcl-100553110",false,"NCT06481826","Glofitamab in Chinese Patients With R\u002FR DLBCL","A Study to Evaluate Glofitamab as Single Agent in Chinese Patients With Relapsed\u002FRefractory Diffuse Large B-Cell Lymphoma","Inclusion Criteria:\n\n1. Histologically-confirmed DLBCL\n2. Participants must have relapsed or failed to respond to at least two lines of prior systemic therapy\n3. Participants must have measurable disease\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Patient with known active infection, or reactivation of a latent infection\n3. Patient with active autoimmune disease or immune deficiency\n4. severe organ failure：LVEF\\\u003C40%；DLCO\\\u003C40%；eGFR\\\u003C30ml\u002Fmin；Bilirubin≥3ULN\n5. Patients who are dependent on the sponsor, the investigator or the trial site","ALL","18 Years","80 Years",{"count":56,"type":57},20,"ESTIMATED","3 Years","OBSERVATIONAL","This study will evaluate the safety and efficacy of glofitamab as a single agent in Chinese patients with relapsed or refractory (R\u002FR) diffuse large B-cell lymphoma (DLBCL) who have failed two or more lines of systemic therapy.",[62],"DLBCL - Diffuse Large B Cell Lymphoma","2026-03-23",{"date":65,"type":66},"2026-03-27","ACTUAL",{"date":68,"type":66},"2024-01-01",{"date":70,"type":57},"2028-12-31",{"name":5,"class":6},1]